Climb Bio
IPOInspired Medicines for Immune-Mediated Diseases
Public · Wellesley Hills, United States · $170.0M raised
- Headquarters
- Wellesley Hills, Massachusetts
- Business Model
- B2B
- Website
- climbbio.com
- Total Funding
- $170.0M
- Last Round
- $110.0M Private EquityApr 2026
- Rounds
- 2
- Type
- Public
About
Clinical-stage biotechnology company developing disease-modifying medicines for immune-mediated diseases.
Summary
Climb Bio is a Biotech company based in Wellesley Hills, United States. It has raised $170.0M in total across 2 rounds, most recently a $110.0M Private Equity round in Apr 2026. Investors include Adage Capital, RA Capital Management and Intermediate Capital Group.
Tech & App Stack
3 technologies & apps tracked
Create a free account — 10 credits a month to unlock the full tech & app stack, funding history, and valuations.
Sign up to view the funding chart
Create a free account — you'll get 10 credits a month to unlock funding history, valuations, and tech stacks.
Funding History
Apr 2026
Sign up to see all 2 rounds
Full funding history, per-round amounts, and investor participation.
Investors
Similar Companies
Global contract research organization providing comprehensive drug development and laboratory ser...
Global fertility clinics platform
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.
Specialty pharmaceutical company
Biopharmaceutical services company
Global oncology biopharmaceutical company developing and commercializing cancer treatments, now r...